Lipomics Technologies to Support Isis Pharmaceuticals in Preclinical and Clinical Studies of Metabolic Drug Candidates
Posted on: Wednesday, 14 February 2007, 09:01 CST
Lipomics Technologies, Inc., a privately held company that specializes in the analysis of lipid metabolites, announced today that it has entered into an agreement with Isis Pharmaceuticals, Inc. to provide lipid-focused support of preclinical and clinical trial testing for various compounds to treat metabolic disease.
Lipomics will retain exclusive rights to develop diagnostic applications based on the data from the studies, while Isis will retain all therapeutic rights. Lipomics seeks to partner with drug companies that see the value in developing companion diagnostic tests that increase the efficacy, safety and cost-effectiveness of a therapeutic.
Sanjay Bhanot, Vice President, Metabolic Diseases R&D at Isis, commented, "We are impressed with Lipomics' capabilities and look forward to working with them as we assess the lipid profiles of compounds we have in our metabolic disease development pipeline."
"We look forward to working with Isis. We believe our approach, which focuses on providing plasma-based mechanistic markers of lipid metabolism, will help to advance their compounds through the clinic," said Steve Watkins, president and chief scientific officer at Lipomics.
About Lipomics
Lipomics Technologies provides industry-leading metabolic assessments for drug research, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate comprehensive, accurate and quantitative profiles of lipid metabolites.
A broad range of bioinformatics and analytical tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.
In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics and enable individualized health management.
More information about Lipomics can be found at www.lipomics.com.
EDITORIAL CONTACTS: Sarina Chohan (916) 371-7974 Contact via http://www.marketwire.com/mw/emailprcntct?id=4F498F9AD7C896D2 Agency Contact Doug Forsyth Alchymia Communications® (541) 482-8744 Contact via http://www.marketwire.com/mw/emailprcntct?id=CEEBDC8AF7E6EAC4
SOURCE: Lipomics Technologies, Inc.
Source: MARKET WIRE
Related Articles
- REMINDER: ORLive Presents: Access to Surgical Intervention for Metabolic Syndrome and Other Diseases
- ORLive Presents: Access to Surgical Intervention for Metabolic Syndrome and Other Diseases
- Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
- OLIGOMERIX Awarded NIH Grant to Develop Novel Drug Discovery Technology for Alzheimer's Disease
- Cherries May Help Reduce Metabolic Syndrome and Heart Disease Risk Factors
- Heart Metabolism Defect Linked to Disease
- ABAXIS Launches 'Avian/Reptilian Profile Plus' Diagnostic Rotor, With Bile Acids, at AAV International Conference in Monterey, Ca
- Lipid Imaging Tool for Drug Development in Metabolic Diseases to Be Presented at Bio-Tech Israel 2005
- Combating Cardiovascular Disease With Compounded Medications: Part 2: Clinical and Compounding Issues for Antihypertensive Drugs
- Can Adoption of Regular Exercise Later in Life Prevent Metabolic Risk for Cardiovascular Disease?
 |
 |
User Comments (0)
RSS Feeds